Company intelligence / Profile preview

TNK SILMA

Moscow, Russia

Ownership: Private
Development stage: Other

Overview

TNK Silma is a Russian pharmaceutical company specializing in the development and production of organosilicon-based medicinal products. The company's flagship product is Enterosgel, an innovative intestinal adsorbent (enterosorbent) used for detoxification and the treatment of various gastrointestinal and systemic conditions. Enterosgel is a hydrogel based on polymethylsiloxane polyhydrate, designed to selectively adsorb toxins and pathogens from the gut without affecting beneficial nutrients. TNK Silma operates its own manufacturing facilities and distributes its products internationally across Europe, Asia, and other regions.

Therapeutic areas: NephrologyImmunologyOtherInfectious DiseasesGastroenterology
Modalities: Small moleculeHydrogel-based drug delivery therapy
Industry: Therapeutic Medical Devices

Beyond the preview

Go deeper on TNK SILMA.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TNK SILMA.

Explore the full profile